Drug Profile

PH 3861

Alternative Names: PH-3861

Latest Information Update: 05 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Phio Pharmaceuticals
Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
Mechanism of Action Programmed cell death 1 receptor expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Liver cancer

Most Recent Events

16 Sep 2021 Preclinical trials in Liver cancer in USA
16 Sep 2021 Pharmacodynamic data from a preclinical trials in Liver cancer released by Phio Pharmaceuticals
16 Sep 2021 Phio Pharmaceuticals plans clinical trials for Liver cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com